SLC6A11: A Potential Drug Target and Biomarker for Neurological Disorders

Target Name: SLC6A11

NCBI ID: G6538

SLC6A11

SLC6A11: A Potential Drug Target and Biomarker for Neurological Disorders

SLC6A11, also known as SLC6A11 gene, is a member of the SLC6A family which consists of six genes that encode for different transport proteins for various neurotransmitters. These proteins play a crucial role in the transportation of neurotransmitters across the blood-brain barrier and are involved in the regulation of neurotransmission. SLC6A11 is a gene that encodes for a protein known as SLC6A11, which is a member of the SLC6A family. This protein is involved in the transport of neurotransmitters and may be a drug target or biomarker.

The SLC6A11 gene is located on chromosome 12q14 and has been implicated in various neurological and psychiatric disorders. Studies have shown that individuals with certain genetic variations in the SLC6A11 gene are at increased risk for conditions such as Alzheimer's disease, Parkinson's disease, and depression. These genetic variations have been associated with the misfolding and aggregation of SLC6A11 protein, which may contribute to the development of these neurological disorders.

SLC6A11 is a transmembrane protein that functions as a carrier for various neurotransmitters, including dopamine, serotonin, and endocannabinoids. It is expressed in various tissues of the brain, including the prefrontal cortex, basal ganglia, and cerebellum. SLC6A11 is involved in the transporter of neurotransmitters across the blood-brain barrier, which is a specialized barrier that separates the brain from the blood and helps to maintain the integrity of the blood-brain barrier.

SLC6A11 has been shown to play a role in the regulation of neurotransmission by modulating the activity of other genes, such as the dopamine receptor. Studies have shown that SLC6A11 can interact with the dopamine receptor and modulate its activity. This interaction between SLC6A11 and the dopamine receptor may be relevant to the treatment of addiction and drug abuse, as drugs that selectively interact with the dopamine receptor may be effective in treating addiction.

SLC6A11 has also been shown to play a role in the regulation of neurotransmission by modulating the activity of other genes, such as the serotonin receptor. Studies have shown that SLC6A11 can interact with the serotonin receptor and modulate its activity. This interaction between SLC6A11 and the serotonin receptor may be relevant to the treatment of depression and other mood disorders, as drugs that selectively interact with the serotonin receptor may be effective in treating these conditions.

In addition to its role in modulating the activity of other genes, SLC6A11 has also been shown to play a role in the regulation of neurotransmission by modulating the structure and function of its own protein. Studies have shown that SLC6A11 can undergo post-translational modifications, such as phosphorylation and ubiquitination, which may alter its stability and function. These modifications may have implications for the regulation of neurotransmission by SLC6A11.

Given the role of SLC6A11 in the regulation of neurotransmission and its involvement in various neurological and psychiatric disorders, it is a promising target for drug development. Studies have shown that SLC6A11 can be modulated by various small molecules, such as those that bind to its transport proteins. These modulations may have implications for the development of drugs that target SLC6A11 and modulate its activity.

In addition to its potential as a drug target, SLC6A11 is also a potential biomarker for various neurological disorders. Studies have shown that individuals with certain genetic variations in the SLC6A11 gene are at increased risk for conditions such as Alzheimer's disease, Parkinson's disease, and depression. These genetic variations have

Protein Name: Solute Carrier Family 6 Member 11

Functions: Mediates sodium- and chloride-dependent transport of gamma-aminobutyric acid (GABA) (PubMed:7874447). Can also mediate transport of beta-alanine and to a lower extent that of taurine and hypotaurine (By similarity)

The "SLC6A11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC6A11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets